IPO registrations (S-1, F-1) · Registrants
Freeline Therapeutics Holdings plc
- SEC CIK
- 1810031 · filings on EDGAR ↗
- Former names
- Freeline Therapeutics Holdings Ltd (2020–2020)
- Registration
- Form F-1, first filed 2020-07-17, last 2020-08-03; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2020-08-10; declared effective 2020-08-06
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- X0
- Business address
- SYCAMORE HOUSE, GUNNELS WOOD ROAD, STEVENAGE, Hertfordshire, X0 SG1 2BP
- EDGAR entity type
- other
- Insiders and CEO pay
- Freeline Therapeutics Holdings plc on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per ADS (F-1/A filed 2020-08-03)
- Final price
- $18.00 per ADS, within the range (424B4 filed 2020-08-10, an initial public offering)
- Shares sold
- 8,823,529
- Gross proceeds
- $158,823,522 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FRLN
- Lead underwriters
- J.P. Morgan (3,308,824 shares); Morgan Stanley (3,088,235 shares); Evercore (1,985,294 shares)
- Syndicate
- Wedbush Securities (441,176)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: FREELINE THERAPEUTICS HOLDINGS PLC EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-07-17 | F-1 | F-1 (foreign registration) | Freeline Therapeutics Holdings plc | 0001193125-20-194813 ↗ |
| 2020-08-03 | F-1/A | F-1/A (amendment) | Freeline Therapeutics Holdings plc | 0001193125-20-207194 ↗ |
| 2020-08-06 | F-1MEF | F-1MEF (added securities) | Freeline Therapeutics Holdings plc | 0001193125-20-212236 ↗ |
| 2020-08-06 | EFFECT | EFFECT (declared effective) | Freeline Therapeutics Holdings plc | 9999999995-20-002056 ↗ |
| 2020-08-06 | EFFECT | EFFECT (declared effective) | Freeline Therapeutics Holdings plc | 9999999995-20-002060 ↗ |
| 2020-08-10 | 424B4 | 424B4 (final prospectus) | Freeline Therapeutics Holdings plc | 0001193125-20-215070 ↗ |
| 2021-09-22 | EFFECT | EFFECT (declared effective) | Freeline Therapeutics Holdings plc | 9999999995-21-003629 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-08-03 | F-1/A | registration statement | $16.00–$18.00 | $17.00 | 7,352,941 | $124,999,997 | Nasdaq FRLN | 4 | primary document; range, price sentence, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2020-08-10 | 424B4 | final prospectus | $18.00 | 8,823,529 | $158,823,522 | Nasdaq FRLN | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | FREELINE THERAPEUTICS HOLDINGS PLC | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), X0 first:
- Abcam plc X0
- Immunocore Holdings plc X0
- Autolus Therapeutics plc X0
- Orchard Therapeutics plc X0
- Achilles Therapeutics plc X0
- Gyroscope Therapeutics Holdings plc X0
- OKYO Pharma Ltd X0
- Exscientia plc X0
- TC BioPharm (Holdings) plc X0
- BioNTech SE 2M
In other datasets, the same topic (Health) in X0:
- Form D issuer: Abcam plc (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health